1、根据2024年年报，公司海外营收占比为51.63%，受益于人民币贬值。 来源：新浪证券-红岸工作室 11月24日，中力股份涨0.74%，成交额4755.94万元，换手率2.53%，总市值147.05亿元。 异动分析 人民币贬值受益+机器人概念+智能物流+注册制次新股+新股与次新股 主力持仓 主力轻度控盘，筹码分布较为分散，主力成交额3644.54万，占总成交额的14%。 技术面：筹码平均交易成本为40.61元 2、根据公司招股说明书：公司自成立以来专注于电动叉车等机动工业车辆的技术研发与产品创新。在 机动工业车辆现有生产技术的基础上，结合行业发展趋势和国内外市场需求，公司以绿色化、数字化、 智能化作为发展方向，充分利用多年技术积累，采用独创的"正向研发" 模式，以客户需求为导向，从 产品外形、功能设计出发，不断开发适应市场需求的产品、工艺与技术，历经多年积淀研发出小金刚、 油改电叉车、搬马机器人等多款具有里程碑意义的产品。公司积极发展和布局移动搬运机器人业务， 2020 年推出具备自动化程度高、灵活性强、安全性好等优势的搬马机器人系列产品，有效减少无效搬 运，降低移动搬运机器人应用门槛。 3、2025年1 ...

Group 1 - The core viewpoint of the news is that Anada's stock has experienced a decline recently, with a notable drop of 2.08% on November 21, 2023, and a total market value of 4.275 billion yuan [1] - Anada's stock price has increased by 4.17% year-to-date, but it has seen declines of 7.74% over the last five trading days, 5.80% over the last twenty days, and 11.82% over the last sixty days [1] - The company has been featured on the "龙虎榜" (a stock trading list) seven times this year, with the most recent appearance on May 20, 2023, where it recorded a net buy of -8.117 million yuan [1] Group 2 - Anada's main business involves the research, production, and sales of electric drive systems for electric two-wheelers, with revenue composition being 82.50% from hub motors, 10.17% from mid-mounted motors, 6.79% from controllers and others, and 0.54% from other sources [1] - As of September 30, 2023, Anada had 12,900 shareholders, an increase of 4.89% from the previous period, with an average of 3,399 circulating shares per person, up by 44.64% [2] - For the period from January to September 2023, Anada achieved operating revenue of 1.597 billion yuan, a year-on-year increase of 34.10%, and a net profit attributable to shareholders of 96.0565 million yuan, up by 13.05% [2] Group 3 - Anada has distributed a total of 145 million yuan in dividends since its A-share listing [3]

11月20日，巍华新材盘中下跌2.00%，截至14:03，报17.60元/股，成交4587.42万元，换手率1.40%，总 市值60.78亿元。 资金流向方面，主力资金净流出771.82万元，特大单买入0.00元，占比0.00%，卖出370.40万元，占比 8.07%；大单买入657.84万元，占比14.34%，卖出1059.27万元，占比23.09%。 责任编辑：小浪快报 资料显示，浙江巍华新材料股份有限公司位于浙江省杭州湾上虞经济技术开发区北塘东路8号，成立日 期2013年10月12日，上市日期2024年8月14日，公司主营业务涉及氯甲苯和三氟甲基苯系列产品研发、 生产和销售。主营业务收入构成为：三氟甲基苯系列79.35%，氯甲苯系列19.71%，其他(补充)0.95%。 巍华新材所属申万行业为：基础化工-化学制品-氟化工。所属概念板块包括：小盘、氟化工、新材料、 融资融券、次新股等。 截至9月30日，巍华新材股东户数1.99万，较上期减少1.68%；人均流通股9287股，较上期增加1.71%。 2025年1月-9月，巍华新材实现营业收入6.60亿元，同比减少15.18%；归母净利润1.09亿元，同比减少 ...

Core Viewpoint - The stock of Aidi Te (爱迪特) has experienced a decline of 2.15% on November 20, with a current price of 43.66 CNY per share, reflecting a market capitalization of 4.653 billion CNY. The company has shown a year-to-date stock price increase of 6.39%, but has faced recent declines over various trading periods [1]. Financial Performance - For the period from January to September 2025, Aidi Te achieved a revenue of 747 million CNY, representing a year-on-year growth of 16.44%. The net profit attributable to shareholders was 142 million CNY, marking a 27.40% increase compared to the previous year [2]. Shareholder Information - As of September 30, Aidi Te had 9,851 shareholders, an increase of 4.66% from the previous period. The average number of circulating shares per shareholder decreased by 4.46% to 7,310 shares [2]. Dividend Distribution - Aidi Te has cumulatively distributed dividends amounting to 49.476 million CNY since its A-share listing [3]. Business Overview - Aidi Te, established on March 15, 2007, is located in Qinhuangdao, Hebei Province. The company specializes in the research, production, and sales of zirconia ceramic blocks and other dental restoration materials. The revenue composition includes 73.74% from dental restoration materials, 19.80% from digital dental equipment, and 6.46% from other products and services [1].

资料显示，苏州天脉导热科技股份有限公司位于苏州市吴中区甪直镇汇凯路68号，成立日期2007年7月 25日，上市日期2024年10月24日，公司主营业务涉及导热散热材料及元器件的研发、生产及销售。主营 业务收入构成为：热管理材料及器件98.37%，其他1.63%。 苏州天脉所属申万行业为：电子-消费电子-消费电子零部件及组装。所属概念板块包括：宁德时代概 念、高派息、融资融券、中盘、次新股等。 截至9月30日，苏州天脉股东户数1.08万，较上期增加6.39%；人均流通股2407股，较上期减少6.00%。 2025年1月-9月，苏州天脉实现营业收入8.18亿元，同比增长18.42%；归母净利润1.43亿元，同比增长 1.54%。 11月20日，苏州天脉盘中下跌2.07%，截至13:16，报165.99元/股，成交1.41亿元，换手率1.59%，总市 值192.02亿元。 资金流向方面，主力资金净流出166.27万元，特大单买入1596.87万元，占比11.31%，卖出1637.93万 元，占比11.60%；大单买入2709.65万元，占比19.19%，卖出2834.85万元，占比20.08%。 苏州天脉今年以来股 ...

Core Viewpoint - The stock of Gangdi Technology has experienced a decline in price and performance metrics, indicating potential challenges in the company's financial health and market position [1][2]. Group 1: Stock Performance - As of November 20, Gangdi Technology's stock price decreased by 2.09%, trading at 68.88 CNY per share, with a market capitalization of 3.835 billion CNY [1]. - Year-to-date, the stock has dropped by 16.49%, with a 3.37% decline over the last five trading days, 8.22% over the last 20 days, and 13.23% over the last 60 days [1]. - The company has appeared on the "龙虎榜" (a stock trading board) once this year, with the most recent appearance on July 22, where it recorded a net buy of -1.9212 million CNY [1]. Group 2: Financial Performance - For the period from January to September 2025, Gangdi Technology reported a revenue of 361 million CNY, reflecting a year-on-year decrease of 3.30%, and a net profit attributable to shareholders of 43.3869 million CNY, down 25.24% year-on-year [2]. - The company has distributed a total of 55.68 million CNY in dividends since its A-share listing [3]. Group 3: Shareholder and Market Information - As of November 10, the number of shareholders for Gangdi Technology increased to 8,646, a rise of 3.35%, with an average of 2,950 circulating shares per shareholder, up 77.33% [2]. - The company operates within the mechanical equipment sector, specifically in automation equipment and industrial control devices, and is associated with concepts such as new industrialization and Industry 4.0 [2].

Core Viewpoint - The stock of Xiaofang Pharmaceutical has experienced fluctuations, with a recent decline of 2.02% and a total market capitalization of 4.826 billion yuan, while the company has shown a year-to-date stock price increase of 16.11% [1] Group 1: Stock Performance - As of November 19, Xiaofang Pharmaceutical's stock price is 30.06 yuan per share, with a trading volume of 24.9066 million yuan and a turnover rate of 1.51% [1] - The stock has seen a decline of 6.12% over the last five trading days, 7.90% over the last 20 days, and 16.50% over the last 60 days [1] - The company has appeared on the "龙虎榜" (a stock trading list) eight times this year, with the most recent appearance on August 4, where it recorded a net buy of 3.9196 million yuan [1] Group 2: Financial Performance - For the period from January to September 2025, Xiaofang Pharmaceutical achieved a revenue of 397 million yuan, representing a year-on-year growth of 8.17%, and a net profit attributable to shareholders of 170 million yuan, up 5.09% year-on-year [2] - Cumulative cash dividends since the A-share listing amount to 353 million yuan [3] Group 3: Shareholder Information - As of November 10, the number of shareholders of Xiaofang Pharmaceutical is 13,700, an increase of 2.88% from the previous period, with an average of 3,956 circulating shares per shareholder, a decrease of 2.80% [2] - The ninth largest circulating shareholder is Guangfa Multi-Dimensional Emerging Stock (003745), holding 753,100 shares as a new shareholder, while several funds have exited the top ten circulating shareholders [3] Group 4: Business Overview - Xiaofang Pharmaceutical, established on August 12, 1993, is located in Fengxian District, Shanghai, and specializes in the research, production, and sales of external-use medications [1] - The company's main business revenue composition includes digestive medications (51.05%), skin medications (39.79%), and ear, nose, and throat medications (9.08%) [1]

Core Viewpoint - Yinosh's stock price has experienced fluctuations, with a year-to-date increase of 28.73% but a recent decline of 9.40% over the past five trading days, indicating volatility in investor sentiment and market conditions [1]. Company Overview - Yinosh Biotechnology Co., Ltd. is located in the China (Shanghai) Pilot Free Trade Zone and was established on May 12, 2010. The company specializes in providing non-clinical research services in the biopharmaceutical sector, with 96.31% of its revenue coming from non-clinical services [1]. - The company was listed on September 3, 2024, and operates primarily in the medical biology sector, focusing on medical research outsourcing [1]. Financial Performance - As of September 30, 2025, Yinosh reported a revenue of 571 million yuan, a year-on-year decrease of 35.33%. The net profit attributable to shareholders was -14.79 million yuan, reflecting a significant decline of 111.14% compared to the previous period [2]. - The company has distributed a total of 45.11 million yuan in dividends since its A-share listing [3]. Shareholder Structure - As of September 30, 2025, the number of shareholders decreased by 9.97% to 4,849, while the average number of circulating shares per person increased by 257.28% to 18,703 shares [2]. - New institutional shareholders include Huatai-PineBridge Healthcare Mixed Fund and Huaxia Stable Growth Mixed Fund, which are now among the top ten circulating shareholders [3].

Group 1 - The core viewpoint of the news is that Tai Li Technology's stock has experienced a significant decline this year, with a drop of 28.66% year-to-date and a market capitalization of 4.175 billion yuan [1] - As of November 18, the stock price was 38.56 yuan per share, with a trading volume of 21.156 million yuan and a turnover rate of 2.36% [1] - The company has seen net outflows of main funds amounting to 37,500 yuan, with large orders buying 1.8637 million yuan, accounting for 8.81%, and selling 1.9012 million yuan, accounting for 8.99% [1] Group 2 - Tai Li Technology, established on April 24, 2003, is located in Zhongshan City, Guangdong Province, and specializes in various home storage products and related functional materials [2] - The company's main business revenue composition includes vacuum packaging (41.98%), flexible connections (22.65%), home life (16.14%), safety protection (8.19%), outdoor equipment (5.35%), biological preservation (4.68%), and others (1.00%) [2] - As of September 30, 2025, the company had 13,600 shareholders, a decrease of 16.71%, with an average of 1,703 circulating shares per person, an increase of 20.06% [2] Group 3 - For the period from January to September 2025, Tai Li Technology achieved operating revenue of 822 million yuan, a year-on-year increase of 6.98%, while the net profit attributable to the parent company was 53.1473 million yuan, a year-on-year decrease of 20.68% [2] - The company has distributed a total of 27.07 million yuan in dividends since its A-share listing [3] - As of September 30, 2025, the seventh largest circulating shareholder is the交银瑞思混合(LOF) fund, holding 300,000 shares as a new shareholder [3]

Core Viewpoint - Yinos's stock price has experienced fluctuations, with a year-to-date increase of 32.48% but a recent decline of 7.04% over the past five trading days [1] Group 1: Stock Performance - As of November 18, Yinos's stock price was 46.62 CNY per share, with a market capitalization of 6.572 billion CNY [1] - The stock has seen a trading volume of 16.86 million CNY and a turnover rate of 0.39% [1] - The stock's performance over various periods includes a 11.13% increase over the last 20 days and a 6.17% increase over the last 60 days [1] Group 2: Financial Performance - For the period from January to September 2025, Yinos reported a revenue of 571 million CNY, reflecting a year-on-year decrease of 35.33% [2] - The company recorded a net profit attributable to shareholders of -14.79 million CNY, a decline of 111.14% year-on-year [2] - Cumulative cash dividends paid since the A-share listing amount to 45.11 million CNY [2] Group 3: Shareholder Information - As of September 30, 2025, the number of Yinos's shareholders was 4,849, a decrease of 9.97% from the previous period [2] - The average number of circulating shares per shareholder increased by 257.28% to 18,703 shares [2] - New institutional shareholders include Huatai-PineBridge Healthcare Mixed Fund and Huaxia Stable Growth Mixed Fund, while several funds exited the top ten shareholders list [2]